Compare Amphastar Pharmaceuticals Inc (AMPH) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Shell PLC — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.74 (market cap $826.08M), while Shell PLC trades at $82.67 (market cap $222.30B). The key difference: Shell PLC is far larger — about 269.1× Amphastar Pharmaceuticals Inc's market cap, and Shell PLC pays a 3.8% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | SHEL | |
|---|---|---|
Market Cap | $826.08M | $222.30B |
Sector | Health | Energy |
52-Week High | $30.81 | $94.15 |
52-Week Low | $16.87 | $70.28 |
Enterprise Value | $1.22B | $274.83B |
Dividend Yield | — | 3.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
SHEL trades at $82.23, up 1.02% on the day, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 12.81 and net income margin of 7.01%. Recent Q1 2026 earnings beat expectations, and the company raised its Q2 outlook despite Middle East production disruptions. Analyst consensus is strongly bullish with a $122.20 price target.
The outlook for SHEL is positive, supported by elevated energy prices and strong gas trading, though geopolitical risks and declining operating cash flow pose headwinds. The stock offers value with attractive valuation multiples and a solid dividend, but investors should monitor production volatility and macroeconomic pressures on energy demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
